Date | Price Target | Rating | Analyst |
---|---|---|---|
7/22/2024 | $33.00 | Buy | H.C. Wainwright |
7/8/2024 | $28.00 | Buy | Chardan Capital Markets |
6/27/2024 | $37.00 | Overweight | Piper Sandler |
12/5/2023 | $34.00 | Buy | Truist |
12/5/2023 | $28.00 | Buy | Jefferies |
12/5/2023 | $23.00 | Overweight | JP Morgan |
12/5/2023 | Outperform | TD Cowen |
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
SC 13G/A - CARGO Therapeutics, Inc. (0001966494) (Subject)
H.C. Wainwright initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $33.00
Chardan Capital Markets initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $28.00
Piper Sandler initiated coverage of CARGO Therapeutics with a rating of Overweight and set a new price target of $37.00
Truist initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $34.00
Jefferies initiated coverage of CARGO Therapeutics with a rating of Buy and set a new price target of $28.00
JP Morgan initiated coverage of CARGO Therapeutics with a rating of Overweight and set a new price target of $23.00
TD Cowen initiated coverage of CARGO Therapeutics with a rating of Outperform
HC Wainwright & Co. analyst Robert Burns initiates coverage on Cargo Therapeutics (NASDAQ:CRGX) with a Buy rating and announces Price Target of $33.
Ongoing Phase 1 study informed dose selection for CARGO's currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced diseaseMost recent, longer-term follow-up data for Stanford Medicine's Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-cel
Chardan Capital analyst Geulah Livshits initiates coverage on Cargo Therapeutics (NASDAQ:CRGX) with a Buy rating and announces Price Target of $28.
Piper Sandler analyst Biren Amin initiates coverage on Cargo Therapeutics (NASDAQ:CRGX) with a Overweight rating and announces Price Target of $37.
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company’s prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision. Below is a look at a few recent notable insider purchases. For more, check out Benzinga’s insider transactions platform. DENTSPLY SIRONA The Trade: DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Gregory T Lucier acquired a total of 3,577 shares at a
Truist Securities analyst Asthika Goonewardene reiterates Cargo Therapeutics (NASDAQ:CRGX) with a Buy and lowers the price target from $34 to $32.
Cargo Therapeutics (NASDAQ:CRGX) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.05) by 17.14 percent.
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
4 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
3 - CARGO Therapeutics, Inc. (0001966494) (Issuer)
424B3 - CARGO Therapeutics, Inc. (0001966494) (Filer)
10-Q - CARGO Therapeutics, Inc. (0001966494) (Filer)
8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)
8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)
EFFECT - CARGO Therapeutics, Inc. (0001966494) (Filer)
424B3 - CARGO Therapeutics, Inc. (0001966494) (Filer)
S-1 - CARGO Therapeutics, Inc. (0001966494) (Filer)
8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)
8-K - CARGO Therapeutics, Inc. (0001966494) (Filer)
10-Q - CARGO Therapeutics, Inc. (0001966494) (Filer)
- All sites activated with 38 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) - - Completed $110 million private placement equity financing, extending cash runway through 2026 - SAN CARLOS, Calif., Aug. 12, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided a business update. "The second quarter was marked by continued execution of our potentially pivotal Phase 2 clinical study for firi-c
Ongoing Phase 1 study informed dose selection for CARGO's currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL)Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced diseaseMost recent, longer-term follow-up data for Stanford Medicine's Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-cel SAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) --
– Appointment adds strategic finance and broad operating experience to Board as Company advances potentially pivotal Phase 2 clinical study for CAR T-cell therapy candidate, firicabtagene autoleucel (firi-cel) – SAN CARLOS, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced the appointment of Jane Pritchett Henderson to its Board of Directors. Ms. Henderson will also serve as a member of the audit and compensation committees. "Jane's appointment exemplifies CARGO's ongoing commitment to strong corporate g
SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will be participating in the following investor conferences. TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAGina Chapman, President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat on Tuesday, May 28, at 11:00 a.m. ET. Jefferies Global Healthcare ConferenceGina Chapman, President and Chief Executive Officer, is scheduled to participate in a fireside chat on Wednesday, J
– Financing includes participation from new and existing investors – – Supports BLA preparation for potentially pivotal Phase 2 study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022) and IND-enabling studies for CRG-023 – – Extends cash runway through 2026 – SAN CARLOS, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that it has entered into a securities purchase agreement for a private investment in public equity financing that is expected to result in gross proceeds of approximately $110.0 mill
- 26 sites activated and over 20 patients dosed in the potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel) (CRG-022); Currently on-track for interim results expected in 1H25 - - Independent Data Monitoring Committee (IDMC) recommended continuation of FIRCE-1 without modifications - - Ongoing follow-up from the Stanford Phase 1 study for firi-cel1 to be presented at the 2024 European Hematology Association (EHA) Congress, highlighting median overall survival of 25.7 months and favorable safety profile at the dose level selected for CARGO's Phase 2 Study - SAN CARLOS, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ
SAN MATEO, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced it has appointed Kapil Dhingra, M.B.B.S., to the Company's Board of Directors. Dr. Dhingra is a medical oncologist and a physician-scientist bringing more than 25 years of strategic clinical development experience in oncology, including cell therapy, with a proven track record in drug development, patient care and academic research. Dr. Dhingra's development experience spans several oncology companies, both as a Board member or in senior leadership
– Potentially pivotal Phase 2 clinical study FIRCE-1 of firicabtagene autoleucel (CRG-022) is rapidly recruiting with 20 sites open to date; interim results expected 1H 2025 – SAN MATEO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today provided a business update and reported financial results for the quarter and year ending December 31, 2023. To date, 20 sites have been initiated and are enrolling for the potentially pivotal Phase 2 clinical study, FIRCE-1. The Phase 2 trial (NCT05972720) is an open-label, multice
SAN MATEO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 44th Annual Cowen Healthcare Conference, taking place March 4-6, 2024, in Boston, Massachusetts. Gina Chapman, President and Chief Executive Officer, is scheduled to participate in a cell therapy corporate panel discussion on Wednesday, March 6, at 9:10 a.m. EST. A live webcast of the panel discussion will be accessible through the Investors section of CARGO's website under News & Events. A replay of the web
SAN MATEO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (NASDAQ:CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients, today announced that the company will participate in the 42nd Annual J.P. Morgan Healthcare Conference, taking place January 8-11, 2024, in San Francisco, California. Gina Chapman, President and Chief Executive Officer, is scheduled to present on Monday, January 8, at 9:45 AM PT. Interested parties can access the live webcast for the presentation in the Investors section of CARGO's website under News & Events. A replay of the webcast will be available after the co